Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial

The Lancet Infectious Diseases, Год журнала: 2023, Номер 23(10), С. 1143 - 1152

Опубликована: Июнь 20, 2023

Язык: Английский

---

COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment

JAMA Network Open, Год журнала: 2024, Номер 7(3), С. e241765 - e241765

Опубликована: Март 13, 2024

Importance With the widespread use of anti–SARS-CoV-2 drugs, accumulating data have revealed potential viral load rebound after treatment. Objective To compare COVID-19 a standard 5-day course antiviral treatment with VV116 vs nirmatrelvir-ritonavir. Design, Setting, and Participants This is single-center, investigator-blinded, randomized clinical trial conducted in Shanghai, China. Adult patients mild-to-moderate within 5 days SARS-CoV-2 infection were enrolled between December 20, 2022, January 19, 2023, randomly allocated to receive either or Interventions group received oral 600-mg tablets every 12 hours on day 1 300 mg 2 through 5. nirmatrelvir-ritonavir nirmatrelvir plus 100 ritonavir for days. followed up other until 28 week 60. Main Outcomes Measures The primary outcome was (VLR), defined as half-log increase RNA copies per milliliter compared completion. Secondary outcomes included reduction cycle threshold value 1.5 more, time VLR, symptom rebound, an more than points score secondary analyzed using full analysis set. Sensitivity analyses protocol Adverse events safety Results set 345 participants (mean [SD] age, 53.2 [16.8] years; 175 [50.7%] men) who (n = 165) 180). Viral occurred 33 (20.0%) 39 (21.7%) ( P .70). Symptom 41 160 (25.6%) 40 163 (24.5%) .82). whole-genome sequencing 24 cases same lineage at baseline each case. Conclusions Relevance In this COVID-19, both common Prolongation duration might be investigated reduce rebound. Trial Registration Chinese Clinical Registry Identifier: ChiCTR2200066811

Язык: Английский

---

A Nanoparticle Vaccine Displaying Conserved Epitopes of the Preexisting Neutralizing Antibody Confers Broad Protection against SARS-CoV-2 Variants

ACS Nano, Год журнала: 2024, Номер 18(27), С. 17749 - 17763

Опубликована: Июнь 27, 2024

The rapid development of the SARS-CoV-2 vaccine has been used to prevent spread coronavirus 2019 (COVID-19). However, ongoing and future pandemics caused by variants mutations underscore need for effective vaccines that provide broad-spectrum protection. Here, we developed a nanoparticle with broad protection against divergent variants. corresponding conserved epitopes preexisting neutralizing (CePn) antibody were presented on self-assembling Helicobacter pylori ferritin generate CePnF nanoparticle. Intranasal immunization mice nanoparticles induced robust humoral, cellular, mucosal immune responses long-lasting immunity. CePnF-induced antibodies exhibited cross-reactivity activity different coronaviruses (CoVs). vaccination significantly inhibited replication pathology Delta, WIV04, Omicron strains in hACE2 transgenic and, thus, conferred these Our constructed nanovaccine targeting can serve as promising candidate universal vaccine.

Язык: Английский

---

The effect of social support on home isolation anxiety and depression among college students in the post-pandemic era: the mediating effect of perceived loss of control and the moderating role of family socioeconomic status

Frontiers in Public Health, Год журнала: 2024, Номер 12

Опубликована: Фев. 9, 2024

Background There is an escalating concern about the rising levels of anxiety and depression among college students, especially during post-pandemic era. A thorough examination various dimensions social support their impact on these negative emotions in students imperative. Aim This study aimed to determine if a perceived loss control mediates relationship between Additionally, it examined whether family socioeconomic status moderates this mediated relationship. Methods We administered online cross-sectional survey China, securing responses from 502 participants. The sample comprised home-isolated impacted by COVID-19. Established scales were employed assess support, anxiety, depression, control, status. Analytical techniques included descriptive statistics, correlation analysis, bootstrap method investigate mediating moderating effects. Results Social was found negatively affect with partially In addition, socio-economic shown moderate process. Furthermore, influenced mediation, higher families exhibiting stronger effect across different support. Conclusion may help develop strategies mitigate lives studies university unexpected public health crises, promote better mental students.

Язык: Английский

---

Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study

Emerging Microbes & Infections, Год журнала: 2024, Номер 13(1)

Опубликована: Апрель 28, 2024

Effectiveness of heterologous booster regimes with ad5 vectored COVID-19 vaccine in a large, diverse population during the national-scale outbreak SARS-CoV-2 omicron predominance China has not been reported, yet. We conducted large-scale cohort-control study six provinces China, and did retrospective survey on attack risk this outbreak. Participant aged ≥18 years five previous trials who were primed 1 to 3 doses ICV received either intramuscular or orally inhaled included heterologous-trial cohort. performed propensity score-matching at ratio 1:4 match participants cohort individually community individuals three-dose as control (ICV-community cohort). From February 4 April 10, 2023, 41504 (74.5%) 55710 completed survey. The median time since most recent vaccination onset symptoms was 303.0 days (IQR 293.0-322.0). rate 55.8%, while that ICV-community 64.6%, resulting relative effectiveness 13.7% (95% CI 11.9 15.3). In addition, higher against associated outpatient visits, admission hospital demonstrated, which 25.1% 18.9 30.9), 48.9% 27.0 64.2), respectively. still offered some additional protection preventing breakthrough infection versus homologous regimen ICV, 10 months after vaccination.

Язык: Английский

---

Optimism bias, judgment of severity, and behavioral change during two stages of the pandemics in China

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Янв. 2, 2025

We investigated the factors and consequences of optimism bias during two critical periods COVID-19 outbreak in China. In February 2020, we conducted Study 1 (N = 4313) to examine initial outbreak. The findings revealed that individuals exhibited toward COVID-19. Additionally, number newly confirmed suspected cases positively influenced bias. Later, December 2022, 2 1767) explore Omicron results indicated persisted, albeit a lesser extent. this study, infections among participants' social relations negatively predicted bias, while judged severity it. Notably, can attenuate positive prediction anxiety by perceived severity, also predicting protective behavior mediating relationship between actions. This study highlights beneficial role both physically psychologically, pandemic.

Язык: Английский

---

Infection with SARS-CoV-2 during the first trimester did not adversely impact perinatal and obstetric outcomes subsequent to in vitro fertilization with frozen embryo transfer: a retrospective cohort study

Journal of Assisted Reproduction and Genetics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 17, 2025

Язык: Английский

---

Protection afforded by post-infection SARS-CoV-2 vaccine doses: A cohort study in Shanghai

eLife, Год журнала: 2025, Номер 13

Опубликована: Фев. 17, 2025

Background: In many settings, a large fraction of the population has both been vaccinated against and infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, quantifying protection provided post-infection vaccination become critical for policy. We aimed to estimate protective effect SARS-CoV-2 reinfection an additional vaccine dose after initial Omicron variant infection. Methods: report retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on infections history. compared incidence status individuals initially during April–May 2022 surge Shanghai who had before that period. Cox models were fit adjusted hazard ratios (aHRs). Results: 275,896 diagnosed real-time polymerase chain reaction-confirmed infection 2022; 199,312/275,896 included analyses dose. Post-infection (aHR 0.82; 95% confidence interval 0.79–0.85). For patients received one, two, or three doses their first infection, 0.84 (0.76–0.93), 0.87 (0.83–0.90), 0.96 (0.74–1.23), respectively. within 30 90 days second wave different degrees (in aHR): 0.51 (0.44–0.58) 0.67 (0.61–0.74), Moreover, all types, but extents, given fully was protective. Conclusions: previously individuals, reinfection. These observations will inform future policy decisions COVID-19 China other countries. Funding: This funded Key Discipline Program Pudong New Area Health System (PWZxk2022-25), Development Application Intelligent Epidemic Surveillance AI Analysis (21002411400), Public Construction (GWVI-11.2-XD08), Commission Disciplines (GWVI-11.1-02), Clinical Research (20214Y0020), Natural Science Foundation (22ZR1414600), Young Talents (2022YQ076).

Язык: Английский

---

Factors influencing urban socioeconomic resilience after the withdrawal of nonpharmaceutical interventions: Evidence from intra-city travel intensity in China

Journal of Transport Geography, Год журнала: 2025, Номер 124, С. 104172 - 104172

Опубликована: Март 5, 2025

Язык: Английский

---

Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China

Nature Communications, Год журнала: 2025, Номер 16(1)

Опубликована: Март 26, 2025

We conducted a multicenter, partially randomized, platform trial to assess the effectiveness of booster dose an aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine (Ad5-nCoV) in Chinese adults (NCT05855408). Between May 23, 2023, and August 28, 4089 eligible participants were equally randomized receive either Ad5-nCoV via oral inhalation at 0.1 mL (IH Ad5-nCoV, n = 2039) injection 0.5 (IM 2050). Additionally, 2008 who declined but consented participate surveillance enrolled control group. All monitored for symptomatic over six-month period primary outcome. From 14 days after vaccination, (15/1000 person-years), 19 (20/1000 34 (37/1000 person-years) cases confirmed IH group, IM respectively, which resulted adjusted 52.3% (95% CI 10.4 74.6) 37.2% -11.2 64.5) Ad5-nCoV. The was associated with lower incidence COVID-19, there is no solid evidence that more effective than In this clinical trial, authors find orally inhaled during following 6 months compared controls haven't received booster. Intramuscular administered Ad5-CoV reduced as well.

Язык: Английский

---